				, 0 g	.000.												
Form PTO-1449 D. Paparatient of Commerce								nmer	ce		0723	Docket No. 96.0222 (A34001)	Serial N 09/785		יבטחטבאו	100	I
(REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT						ŊΤ	Applicant Montelaro et al.		CENT								
BY APPLICANT (Use several sheets if necessary)							g Date uary 16, 2001	Group 1646		-H 160	3 20						
(Ose several sheets in necessary)											·	0/2900	01	ED			
							-										
							. "		,	-							
									Ţ	U.S. PA	TENT	DOCUMENTS					
*Exam. Init.					Doo	cument	No.			D	ate	Name		Class	Subclass	Filing App	Date if pro.
ci	1	Τ	5	9	4	5	5	0	7	08/31	/99	Montelaro et al.					

FOREIGN PATENT DOCUMENTS																	
		Document No.								Date		Country		Class	Subclass	<u>Trans</u> Yes	lation No

Montelaro et al.

02/03/98

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

File,TM. "Overview of Resistance in the 1990s", Chest. 115:3S-8S. March 1999 Supplement

Friedrich et al., "Salt-Resistant Alpha-Helical Cationic Antimicrobial Peptides", Antimicrobial Agents and Chemotherapy, 43: 1542-1548, 1999

Hancock. R.E., "Host Defence (Cationic) Peptides: What Is Their Future Clinical Potential?", Drugs, 57: 469-473, Adis International Limited, 1999.

Examiner			Date Considered		
2,141111101) .	7-7-		7-7-05	
-	-n			1	

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1	449 U.S. Department of Commerce
(REV. 2-82)	Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. 072396.0222 (A34001)	Serial No. 09/785,058	130 H3)
Applicant Montelaro et al.		O 3
Filing Date February 16, 2001	Group 1646	2001 600/25
		8 0

swl	5	Scott, Yan, and Hancock, "Biological Properties of Structurally Related α-Helical Cationic Antimicrobial Peptides", <i>Infection & Immunity</i> , 67: 2005-2009, Apr. 1999
swl	6	Tencza et al., "Lentivirus-derived antimicrobial peptides: increased potency by sequence engineering and dimerization", <i>Journal of Antimicrobial Chemotherapy</i> , 44: 33-41, 1999
mL.	8	Beary et al., "Interruption of T-cell signal transduction by lentivirus lytic peptides from HIV-1 transmembrane protein", <i>Journal of Peptide Research</i> , <u>51</u> : 75-79, 1998
مىد	9	Hwang and Vogel, "Structure-function relationships of antimicrobial peptides", Biochem. Cell Biol., <u>76</u> : 235-246, 1998
suL	10	Comardelle et al., "A Synthetic Peptide Corresponding to the Carboxy Terminus of Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein Induces Alterations in the Ionic Permeability of <i>Xenopus laevis</i> Oocytes", <i>AIDS Research & Human Retroviruses</i> , <u>13</u> : No. 17, pp.1525-1532, 1997.
SUL	11	Ganz and Lehrer, "Antimicrobial peptides of leukocytes", Current Opinion in Hematology, 4: 53-58, 1997
SWL	12	Tencza et al., "Novel Antimicrobial Peptides Derived from Human Immunodeficiency Virus Type 1 and Other Lentivirus Transmembrane Proteins", Antimicrobial Agents & Chemotherapy, 41: 2394-2398, 1997
SwL	13	Tencza et al., "Calmodulin-Binding Function of LLP Segments from the HIV Type 1 Transmembrane Protein Is Conserved among Natural Sequence Variants", AIDS Research & Human Retroviruses, 13: No. 3, 263-269, 1997
SwL	14	Arroyo et al., "Membrane Permeabilization by Different Regions of the Human Immunodeficiency Virus Type 1 Transmembrane Glycoprotein gp41", <i>J. Virol.</i> 69: 4095-4102, 1995.
	<u> </u>	

Examiner	Servi	Date Considered	7-3-03	

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUL O 2 2001 B				Page 3
Form PTO-1449 U.S. Department of Commerce	Atty. Docket No. 072396.0222 (A34001)	Serial No. 09/785,058	ECH CI	ال
(REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT	Applicant Montelaro et al.	ENTER	ור 0 ז	
BY APPLICANT (Use several sheets if necessary)	Filing Date February 16, 2001	Group 1646	1600/2900	2001
(60000000000000000000000000000000000000			900	7

sul	15	Tencza et al., "Effect of Amino Acid Substitutions on Calmodulin Binding and Cytolytic Properties of the LLP-1 Peptide Segment of Human Immunodeficiency Virus Type 1 Transmembrane Protein", <i>Journal of Virology</i> , 69: 5199-5202, 1995
swL	16	Yuan et al., "Characterization of the Calmodulin Binding Domain of SIV Transmembrane Glycoprotein by NMR and CD Spectroscopy", <i>Biochemistry</i> , 34: 10690-10696, 1995.
SUL	17	Zanetti, Gennaro and Romeo, "Cathelicidins: a novel protein family with a common propregion and a variable C-terminal antimicrobial domain", FEBS Letters, 374:1-5, 1995
swL	18	Merrifield et al., "Design and synthesis of antimicrobial peptides", Antimicrobial Peptides, Ciba Foundation Symposium, , 5-6, 1994.
swL	19	Moore et al., "Preliminary Experimental Anticancer Activity of Cecropins", <i>Peptide Research</i> , 7:265-269, 1994.
swL	20	Miller et al., "Identification of a Calmodulin-Binding and Inhibitory Peptide Domain in the HIV-1 Transmembrane Glycoprotein", 1993, AIDS Reseach and Human Retroviruses, 2: 1057-1066.
swl	21	Miller et al., "Alterations in Cell Membrane Permeability by the Lentivirus Lytic Peptide (LLP-1) of HIV-1 Transmembrane Protein", <i>Virology</i> , <u>196</u> : 89-1000, 1993
swL	22	Blondelie et al., "Design of Model Amphipathic Peptides Having Potent Anitmicrobial Activities", <i>Biochemistry</i> , 31:12688-12694, 1992
SuL	23	Srinivas et al., "Membrane Interactions of Synthetic Peptides Corresponding to Amphopathic Helical Segments of the Human Immunodeficiency Virus Type-1 Envelope Glycoprotein", Journal of Biological Chemistry, 267:7121-7127, 1992
sul	24	Wild et al., ""A synthetic peptide inhibitor of human immunodeficiency virus replication: Correlation between solution structure and viral inhibition", <i>Proc. Natl. Acad. Sci. USA</i> , <u>89</u> : 10537-10541, 1992.

Date Considered Examiner 7-3-03

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUL 0 2 2001		•	Page 4 of
Form PTO-1449 U.S. Department of Commerce	Atty. Docket No. 072396.0222 (A34001)	Serial No. 09/785,058	ECI JUL (
(REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT	Applicant Montelaro et al.	三 V 3 20 3 160	
BY APPLICANT (Use several sheets if necessary)	Filing Date February 16, 2001	Group 1646	ΞD 01 0/2900

Sul 25	Fontenot et al., "A Survey of Potential Problems and Quality Control in Peptide Synthesis by the Fluorenylmethoxycarbonyl Procedure", <i>Peptide Research</i> , 4:19-25, 1991
5wL 26	Miller et al., "A Structural Correlation Between Lentivirus Transmembrane Proteins and Natural Cytolytic Peptides", AIDS Research & Human Retroviruses, 7:511-519, 1991.
27 SuL	Eisenberg and Wesson, "The Most Highly Amphiphilic α-Helics Include Two Amino Acid Segments in Human Immunodeficiency Virus Glycoprotein 41", <i>Biopolymers</i> , 29: 171-177, 1990
SwL 28	Eisenberg et al., "The hydrophobic moment detects periodicity in protein hydrophocity", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , <u>81</u> :140-144, 1984
Ful 29	Chou et al., "Prediction of The Secondary Structure of Proteins From Their Amino Acid Sequence", Adv Enz Relat Areas Mol Bio, 47: 45-146, 1978.
5WL 30	Garnier et al., "Analysis of the Accuracy and Implications of Simple Methods for Predicting the Secondary Structure of Globular Proteins", <i>J. Mol. Biol.</i> , 120: 97-120, 1978

Examiner South	Date Considered	7-1-63	

^{*} Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.